-
Consensus Rating
HoldBased on 28 Analyst Ratings
-
Consensus Price Target
$57.0070.81% Upside
Longboard Pharmaceuticals, Inc. Frequently Asked Questions
-
What analysts cover Longboard Pharmaceuticals, Inc.?
Longboard Pharmaceuticals, Inc. has been rated by research analysts at H.C. Wainwright, Truist Financial, Robert W. Baird, Cantor Fitzgerald, B.Riley Financial, Guggenheim in the past 90 days.